Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 02, 2010 | Director, Chairman, President & CEO | Open market or private purchase of non-derivative or derivative security | Form 4 | 11,898 | $0.05 | 11,898 | |
| Mar 16, 2010 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | 1,708 | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 19, 2010 | VP, Pharmacology & Biology | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.